Sangamo Therapeutics
SGMO
SGMO
170 hedge funds and large institutions have $955M invested in Sangamo Therapeutics in 2017 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
15% more funds holding
Funds holding: 148 → 170 (+22)
10% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 49
0.7% more ownership
Funds ownership: 65.37% → 66.07% (+0.7%)
Holders
170
Holding in Top 10
6
Calls
$34.4M
Puts
$24.7M
Top Buyers
| 1 | +$41.2M | |
| 2 | +$17.9M | |
| 3 | +$15.2M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.99M |
| 5 |
PP
PDT Partners
New York
|
+$7.74M |
Top Sellers
| 1 | -$18.8M | |
| 2 | -$13.1M | |
| 3 | -$12.8M | |
| 4 |
Millennium Management
New York
|
-$10.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.4M |